In tumors such as pancreatic adenocarcinoma, hepatocellular carcinoma, and pancreatic cancer, the scores of m6A-modified regulatory genes are significantly correlated with the expression of CTLA-4 and can be used to predict prognosis and response to immunotherapy (144–146). This evidence concerns the gene CTLA4 and familial pancreatic carcinoma.